Obesity is a relapsing condition that affects nearly 890 million adults across the world. It significantly contributes to death, illness, and healthcare cost to large population. Among available treatments, GLP-1 receptor agonists have become a core part of obesity pharmacotherapy.  Tripeptide, a GIP/GLP-1 receptor agonist, was initially approved for type 2 diabetes but is now showing greater weight-loss effects. New research trials suggested that participants with obesity w